ERBB2 and breast carcinoma: We performed integrated analysis of three longitudinal samples from a single patient to further assess the immune environment and expression changes over time in the setting of trastuzumab-treated HER2+ breast cancer, including: needle biopsy at the time of diagnosis (primary tumor, H & E staining shown in Figure 5A,B), resected tumor at definitive surgery following four cycles of trastuzumab (S10 tumor listed in Table 1 and Table 2, H & E staining shown in Figure 5G,H), and chest wall biopsy at recurrence seven months post therapy (H & E staining shown in Figure 5M,N).